Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, Glucotrack, Inc. (the “Company”) received a determination from The Nasdaq Stock Market LLC (“Nasdaq”) to delist the Company’s securities for failure to comply with the $1.00 minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Following a hearing, a Nasdaq Hearings Panel (the “Panel”) granted the Company an exception to regain complia…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth above in

by reference. The Notes, the Warrants, the Placement Agent Warrants and the shares of Common Stock issuable upon conversion of the Notes or exercise of the Warrants or Placement Agent Warrants, as applicable, and any Penalty Shares that may be issued, were, or upon issuance will be, issued and sold by the Company in reliance upon the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). As previously disclosed in the Company’…

Entry Into a Material Definitive Agreement. Private Placement On October 22, 2026, Glucotrack, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company issued to the Investors senior secured convertible promissory notes (the “Notes”) in the aggregate principal amount of $2,564,102.65 for an aggregate cash purchase price of $2,000,000, reflecting a 22% original issue discount. The Notes…

Entry Into a Material Definitive Agreement. On October 13, 2026, Glucotrack, Inc. (the “Company”) entered into a Waiver Agreement (the “Waiver”) with certain holders (the “Holders”) of warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued pursuant to the Securities Purchase Agreement, dated as of July 14, 2026, by and among the Company and the Holders (such agreement, the “Purchase Agreement,” and such warrants, the “Existing Warran…

by reference. The New Warrants and the Warrant Shares will be issued by the Company to the Holders in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), afforded by Section 4(a)(2) of the Securities Act.

Entry Into a Material Definitive Agreement. As previously disclosed, on July 14, 2026, Glucotrack, Inc. (the “Company”) entered into a securities purchase agreement as supplemented by a joinder dated August 4, 2026 (the “Purchase Agreement”), with certain investors (the “Bridge Investors”) pursuant to which the Company issued to the Bridge Investors senior secured convertible promissory notes (the “Bridge Notes”) and common stock purchase warrants (the “Bridge Warrants”). Beginning on Septemb…

Entry into a Material Definitive Agreement. On September 24, 2026, Glucotrack, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), relating to the registered direct offering and sale of an aggregate of (i) 169,388 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants” and…

Director — Paul V. Goode: A director resigned immediately citing a potential conflict of interest regarding a merger agreement, which is a non-routine departure with governance implications.

Entry Into a Material Definitive Agreement. As previously disclosed, on August 4, 2026, Glucotrack, Inc. (the “Company”) entered into a securities purchase agreement with an investor (the “PIPE Purchaser”) for a private placement of securities. At the closing, the Company issued pre-funded warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and common stock purchase warrants (the “Common Warrants”) to purchase shares of Common Stock. On…

Entry Into a Material Definitive Agreement. Private Placement On September 10, 2026, Glucotrack, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company issued senior secured convertible promissory notes (the “Notes”) in the aggregate principal amount of $11,596,172.68, in exchange for (i) aggregate cash consideration of $4,500,000 and (ii) the surrender and exchange of $4,545,014.69 i…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth above in

by reference. The Notes, the Warrants, the Placement Agent Warrants and the shares of Common Stock issuable upon conversion of the Notes or exercise of the Warrants or Placement Agent Warrants, as applicable, and any Penalty Shares that may be issued, were, or upon issuance will be, issued and sold by the Company in reliance upon the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”).

Entry Into a Material Definitive Agreement. On September 4, 2026, Glucotrack, Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B (“Alto”), Erik Emerson, RXRR Capital Partners LLC and Lōkahi Therapeutics, Inc. The Settlement Agreement resolves certain disputes among the parties relating to indebtedness owed to Alto by Apimeds Pharmaceuticals US, Inc., which Alto asserted had an…

by reference. The Note was issued, and any shares of common stock issuable upon conversion of the Note will be issued, in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Glucotrack, Inc. Date: September 9, 2026 By: /s/ Erik Emerson Na…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth above in

Completion of Acquisition or Disposition of Assets. The disclosure set forth under

by reference. The issuance of the Commitment Shares will be made by the Company to the Investor upon the exemptions from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D thereunder.

Entry Into A Material Definitive Agreement. On August 7, 2026, Glucotrack, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to the Common Stock Purchase Agreement, dated July 14, 2026 (the “ELOC Purchase Agreement”), by and between the Company and White Lion Capital, LLC (the “Investor”). The Amendment modifies Section 6.4(a) of the ELOC Purchase Agreement to provide that the Company will issue 2,505,513 shares of Common Stock (the “Commitment Shares”) to the Investor withi…

by reference. The Follow-On Bridge Notes and Follow-On Bridge Warrants (and the shares of Common Stock issuable upon conversion of the Follow-On Bridge Notes and exercise of the Follow-On Bridge Warrants) were, or in the case of the underlying shares, will be, issued and sold by the Company to the New Investors in reliance upon the exemptions from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) afforded by Section 4(a)(2) of the Securities Act an…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth above in

Entry Into a Material Definitive Agreement. On August 4, 2026, Glucotrack, Inc. (the “Company”) entered into a series of definitive agreements providing for (i) a follow-on investment in the Company’s existing bridge financing (the “Bridge Follow-On”) and (ii) an interim private placement (the “Interim PIPE” and, together with the Bridge Follow-On, the “Follow-On Financing”). This section describes the material provisions of the Follow-On Financing but does not purport to describe all of the…

Unregistered Sales of Equity Securities To the extent required by

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. To the extent required by

Entry Into a Material Definitive Agreement. On July 24, 2026, the Company entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note previously issued to the Investor on September 12, 2025, in the original principal amount of $3,600,000, with such principal subsequently reduced by $600,000 pursuant to that certain exchange agreement, dated April 13, 2026, by and between the Company and the Investor (the “First Exchan…